<?xml version="1.0" encoding="UTF-8"?>
<p>mRNA-based vaccines can be designed and developed using mRNAs-encoding antigens, to be translated in the human body. This approach was recently launched by Moderna to develop vaccine platforms against SARS-CoV-2 through the use of mRNA-1273, encoding viral S protein [
 <xref rid="B64" ref-type="bibr">64–66</xref>]. In May 2020, Moderna received the US FDA clearance to start a Phase II study on lipid nanoparticles (LNP)-encapsulating S protein-encoding mRNA-1273 (
 <xref ref-type="fig" rid="F2">Figure 2</xref>) [
 <xref rid="B67" ref-type="bibr">67</xref>]. Several studies are currently ongoing in terms of mRNA vaccine development against SARS-CoV-2. Another similar approach involves administration of mRNA encoding an antibody protein.
</p>
